HC Wainwright Boosts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of $1.39 per share for the year, up from their previous forecast of $1.26. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

Other equities research analysts also recently issued reports about the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $35.19 on Wednesday. The firm has a 50-day moving average price of $30.92 and a two-hundred day moving average price of $28.38. TG Therapeutics has a 12-month low of $12.93 and a 12-month high of $37.58. The company has a market capitalization of $5.48 billion, a P/E ratio of -351.86 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TGTX. State Street Corp boosted its position in TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics in the 4th quarter valued at $55,237,000. Principal Financial Group Inc. boosted its holdings in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares in the last quarter. Raymond James Financial Inc. bought a new stake in TG Therapeutics during the 4th quarter worth $14,508,000. Finally, Braun Stacey Associates Inc. acquired a new position in TG Therapeutics in the 4th quarter worth about $13,328,000. 58.58% of the stock is owned by institutional investors.

Insider Buying and Selling at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.